4320 Forest Park Avenue
About ImmunoPhotonicsImmunophotonics is a biotech company developing a proprietary drug for use in a therapeutic cancer vaccine (inCVAX). This novel immunotherapy begins with a two injection procedure into any one accessible tumor, intended to liberate and utilize the patient’s tumor antigens to generate a systemic antitumor immune response.
Founder and CEO: Tomas Hode, PhD
COO Lu Alleruzzo, MBA
CDO (Chief Drug Dev. Officer): Joe Raker, PhD
Tweets by Immunophotonics
5 articles with ImmunoPhotonics
Immunophotonics Announces First Patient Treated in Clinical Study Evaluating IP-001 in Patients with Advanced Solid Tumors
Immunophotonics, Inc. announces the first patient treated in the phase 1b/2a clinical trial examining IP-001 in thermally ablated solid tumors.
10/9/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the treatment of solid and metastatic cancers, has bolstered its expertise through the appointment of Jonathan Knowles, Ph.D. to its Board of Directors.
St. Louis, Missouri is one of the fastest-growing and top-ranked emerging life sciences markets in the U.S., ranking sixth in a recent CBRE Research report.
ImmunoPhotonics Announces First Patient Dosed In A Randomized, Controlled Breast Cancer Clinical Trial For Incvax – A Novel Investigational Immuno-Oncology Therapy